Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3004492 | 0.98 | ATM (0.74) | ATML3MBTL1KMT2ATDP1MEN1 | |
| SCHEMBL6043707 | 0.93 | ATM (0.74) | ATML3MBTL1KMT2ATDP1MEN1 | |
| SCHEMBL9353827 | 0.91 | ATM (0.71) | ATML3MBTL1KMT2ATDP1MEN1 | |
| SCHEMBL6043908 | 0.91 | ATM (0.71) | ATML3MBTL1KMT2ATDP1MEN1 | |
| SCHEMBL19244611 | 0.89 | ATM (0.68) | ATML3MBTL1KMT2ATDP1MEN1 | |
| SCHEMBL22623058 | 0.86 | ATM (0.64) | ATML3MBTL1KMT2ATDP1MEN1 | |
| SCHEMBL2645083 | 0.85 | ATM (0.68) | ATML3MBTL1KMT2ATDP1MEN1 | |
| SCHEMBL19574089 | 0.85 | ATM (0.95) | ATML3MBTL1KMT2ATDP1MEN1 | |
| SCHEMBL28366947 | 0.85 | ATM (0.85) | ATML3MBTL1KMT2ATDP1MEN1 | |
| SCHEMBL10722542 | 0.85 | ATM (0.85) | ATML3MBTL1KMT2ATDP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| CN-119816491-A | New spirocyclohexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2025-04-11 | — | — | CN | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| US-9187435-B2 | Bridged Spiro[2.4]heptane ester derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-11-17 | — | — | US | disclosed |
| EP-2640699-B1 | BRIDGED SPIRO[2,4]HEPTANE ESTER DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2015-10-07 | — | — | EP | disclosed |
| EP-2640699-A2 | BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2013-09-25 | — | — | EP | disclosed |
| US-20130231319-A1 | Bridged Spiro[2.4]heptane Ester Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-09-05 | — | — | US | disclosed |
| WO-2012066488-A2 | BRIDGED SPIRO[2.4]HEPTANE ESTER DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| EP-1169318-A1 | PRODRUGS OF THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2002-01-09 | — | — | EP | disclosed |
| US-6232273-B1 | MACROMOLECULAR COMPOUND WITH NITROGEN-CONTAINING RING PENDANT TO THE POLYMER CHAIN, SUCH AS POLYMER OF (METH)ACRYLOYL PYRROLIDINE, PYRROLIDINOCARBONYLETHYL (METH)ACRYLATE, 2-OXO-PYRROLIDINO-ETHYL (METH)ACRYLATE, ETC. | NIPPON SHOKUBAI CO., LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| WO-2000061577-A1 | PRODRUGS OF THROMBIN INHIBITORS | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-19 | — | — | WO | disclosed |
| US-5958837-A | 2-(PHENYLMETHOXY OR CARBONYLOXY-(1,4-PHENYLENE)-),3-HALO,5-HALOALKYLPYRIDINES; HERBICIDES EFFECTING DESICCATION AND DEFOLIATION OF PLANTS; GOOD ACTIVITY AND BETTER TAILORED CONTROL OF WEEDS | BASF AKTIENGESELLSCHAFT (DE) | 1999-09-28 | — | — | US | disclosed |
| EP-0802904-B1 | SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES | BASF AG (DE) | 1998-09-09 | — | — | EP | disclosed |
| EP-0828778-A1 | CLATHRATE HYDRATE INHIBITOR AND METHOD OF INHIBITING THE FORMATION OF CLATHRATE HYDRATES USING IT | NIPPON SHOKUBAI CO., LTD. (JP) | 1998-03-18 | — | — | EP | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| WO-1996038492-A1 | CLATHRATE HYDRATE INHIBITOR AND METHOD OF INHIBITING THE FORMATION OF CLATHRATE HYDRATES USING IT | NIPPON SHOKUBAI CO., LTD. (JP) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996021647-A1 | SUBSTITUTED 2-PHENYLPYRIDINES AS HERBICIDES | BASF AKTIENGESELLSCHAFT (DE) | 1996-07-18 | — | — | WO | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | ATM 4043/4885L3MBTL1 637/4885KMT2A 2309/4885 |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | ATM 2297/4885L3MBTL1 1235/4885KMT2A 4742/4885 |
| US-20130231319-A1 | Bridged Spiro[2.4]heptane Ester Derivatives | ADH1A, ADH1C, NAPA | ATM 3999/4885L3MBTL1 1642/4885KMT2A 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.